Cargando…

Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand?

Acute kidney injury (AKI) is a common complication of liver cirrhosis and is of the utmost clinical and prognostic relevance. Patients with cirrhosis, especially decompensated cirrhosis, are more prone to develop AKI than those without cirrhosis. The hepatorenal syndrome type of AKI (HRS–AKI), a spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chancharoenthana, Wiwat, Leelahavanichkul, Asada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Opinion Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676545/ https://www.ncbi.nlm.nih.gov/pubmed/31391766 http://dx.doi.org/10.3748/wjg.v25.i28.3684

Ejemplares similares

The (Poly)phenol-Carbohydrate Combination for Diabetes: Where Do We Stand?
por: de Matos, Ana Marta, et al.
Publicado: (2023)

Urinary exosomal activating transcriptional factor 3 as the early diagnostic biomarker for sepsis-induced acute kidney injury
por: Panich, Tanaporn, et al.
Publicado: (2017)

Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review
por: Chancharoenthana, Wiwat, et al.
Publicado: (2023)

Ion Channels and Transporters in Immunity—Where do We Stand?
por: Hoeger, Birgit, et al.
Publicado: (2022)

Going Micro in Leptospirosis Kidney Disease
por: Chancharoenthana, Wiwat, et al.
Publicado: (2022)

Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease
por: Chancharoenthana, Wiwat, et al.
Publicado: (2017)

Comparative Long-Term Renal Allograft Outcomes of Recurrent Immunoglobulin A with Severe Activity in Kidney Transplant Recipients with and without Rituximab: An Observational Cohort Study
por: Chancharoenthana, Wiwat, et al.
Publicado: (2021)

COVID-19 and liver injury: where do we stand?
por: Papadopoulos, Nikolaos, et al.
Publicado: (2020)

Ablative Management of Persistent Atrial Fibrillation (PeAF) with Posterior Wall Isolation (PWI): Where Do We Stand?
por: Baqal, Omar, et al.
Publicado: (2023)

Alteration of urinary neutrophil gelatinase–associated lipocalin as a predictor of tacrolimus-induced chronic renal allograft fibrosis in tacrolimus dose adjustments following kidney transplantation
por: Chancharoenthana, Wiwat, et al.
Publicado: (2018)

The leaky gut and the gut microbiome in sepsis – targets in research and treatment
por: Chancharoenthana, Wiwat, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

Dermatology education in skin of colour: where we are and where do we go?
por: Onasanya, Joshua, et al.
Publicado: (2021)

Lacticaseibacillus rhamnosus dfa1 Attenuate Cecal Ligation-Induced Systemic Inflammation through the Interference in Gut Dysbiosis, Leaky Gut, and Enterocytic Cell Energy
por: Tongthong, Tongthong, et al.
Publicado: (2023)

Diabetic kidney disease, revisited: where do we stand?
por: Cha, Dae Ryong
Publicado: (2022)

Gut microbiota and autism spectrum disorders: where do we stand?
por: Zyoud, Sa’ed H., et al.
Publicado: (2023)

Agreement and Precision Analyses of Various Estimated Glomerular Filtration Rate Formulae in Cancer Patients
por: Chancharoenthana, Wiwat, et al.
Publicado: (2019)

More Prominent Inflammatory Response to Pachyman than to Whole-Glucan Particle and Oat-β-Glucans in Dextran Sulfate-Induced Mucositis Mice and Mouse Injection through Proinflammatory Macrophages
por: Hiengrach, Pratsanee, et al.
Publicado: (2022)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Assessment of Liver Function With MRI: Where Do We Stand?
por: Río Bártulos, Carolina, et al.
Publicado: (2022)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Repurposing of High-Dose Erythropoietin as a Potential Drug Attenuates Sepsis in Preconditioning Renal Injury
por: Chancharoenthana, Wiwat, et al.
Publicado: (2021)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Pregnancy-related acute kidney injury in the African continent: where do we stand? A systematic review
por: Shalaby, Ahmed Saad, et al.
Publicado: (2022)

Topical Pramoxine in Chronic Pruritus: Where do We Stand?
por: Agarwal, Akash, et al.
Publicado: (2021)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2018)

Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading?
por: Daoud, Ahmed, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2020)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Role of Endoscopic Ultrasound in Liver Disease: Where Do We Stand?
por: Pavic, Tajana, et al.
Publicado: (2021)

Personalized medicine – where do we stand?: Pouring some water into wine: a realistic perspective
por: Gundert-Remy, Ursula, et al.
Publicado: (2012)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2jqchm42mns3qpqvjdd8a6o408